BIO Ventures for Global Health

What BIO Ventures for Global Health does

Revenue is generated through philanthropic grants and corporate donations from a concentrated set of major pharmaceutical partners — Pfizer (founding), Takeda, Johnson & Johnson, Bristol Myers Squibb, Bayer, and Amgen — supplemented by NIH/NCI funding for specific programs such as AMPERE, bilateral/multilateral donors, and foundation support. Services are delivered free of charge to LMIC partner governments, hospitals, and healthcare professionals under formal Memoranda of Understanding with national ministries of health. Distribution occurs through direct government and hospital partnerships, fellowship placements, digital seminars, and conference participation (BIO International Convention Africa Pavilion, AORTIC, SIOP Africa, World Health Assembly). Programmatic scale metrics include 4,000+ cancer patients treated, 26,000+ individuals trained, 4,100+ participating hospitals, 200+ research collaborations, and 13 North-South R&D partnerships in 2024 alone. BVGH is governed by a Board of Directors including former BIO President & CEO James Greenwood as Chairman and Robert Chess, with operations centered on a lean ~10-person Seattle-based team augmented by global expert networks and academic partners (University of Pennsylvania, Memorial Sloan Kettering, AAPM, ASCO, ASCP).

Name

BIO Ventures for Global Health

Legal name

BIO Ventures for Global Health

Website

http://www.bvgh.org/

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

11–50 employees

Short description

BIO Ventures for Global Health is a Seattle-based nonprofit that catalyzes public-private partnerships between African governments, hospitals, pharmaceutical companies, and academic institutions to expand cancer care, clinical trial capacity, and infectious disease research across low- and middle-income countries.

Ownership category

akta.pro rank

Product category

Global Health Nonprofit Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Health Services (8000), Services-Social Services (8300), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industries

Health Systems Strengthening & Global Health Technical Assistance (BPADAEAH), Communicable Disease Prevention & Control (HIV/AIDS, TB, Malaria, NTDs) (BPADAIAA), Community Health, Health Promotion & Behavior Change (SBCC) (BPADAIAL)

Keywords

• Global health partnerships
• Cancer care capacity
• Clinical trial access
• Health workforce training
• Public-private partnerships

Headquarters

HQ city

Settle

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Philanthropic Grants and Donations: BVGH is a nonprofit organization that raises funds from pharmaceutical companies, foundations, government agencies (e.g., NIH/NCI for programs like AMPERE), and bilateral/multilateral donors. Revenue supports program delivery, capacity building, and partnership management across Africa.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels9 records

Core offering

BVGH is a nonprofit organization that strategically develops and manages programs across the for-profit and non-profit sectors to catalyze innovative research and development, expand research and healthcare capacity in low- and middle-income countries (LMICs), and increase access to high-quality healthcare. Its core offerings include public-private partnership programs such as the African Access Initiative (AAI), the African Consortium for Cancer Clinical Trials (AC3T), and the Global Innovation Alliance (GIA), complemented by digital platforms (BVGH Learn, AC3T Online Platform, GIANTS Online Platform) and the Let's Talk About Cancer awareness initiative.

Product overview

BIO Ventures for Global Health operates as a nonprofit organization managing a portfolio of public health programs rather than a unified commercial product. The organization's offerings include the African Access Initiative (AAI), a comprehensive cancer care program that encompasses the African Consortium for Cancer Clinical Trials (AC3T) with its online platform for profiling African clinical trial sites. For infectious diseases, BVGH manages the Global Innovation Alliance (GIA), which includes the GIA Network of Trial Sites (GIANTS) platform. Educational capabilities are delivered through BVGH Learn, an on-demand training platform, and the Let's Talk About Cancer awareness initiative. The programs collectively focus on capacity building, clinical research partnerships, drug access, and health education across low- and middle-income countries in Africa.

Differentiator

Problem solved

Functional benefit

Brands

• African Access Initiative (AAI): Public-private partnership targeting the growing cancer crisis in Africa through sustainable access to cancer medicines, clinical capacity building, and clinical trials.
• African Consortium for Cancer Clinical Trials (AC3T)
• Global Innovation Alliance (GIA)
• GIANTS (GIA Network of Trial Sites)
• BVGH Learn
• Let's Talk About Cancer

Products and services

• African Access Initiative (AAI) A public-private partnership program that accelerates access to cancer treatment in Africa by engaging stakeholders across sectors. AAI establishes sustainable access to cancer medicines and technologies, builds clinical oncology capacity, addresses the cancer data gap through clinical trials, and expands awareness of cancer in Africa.
• African Consortium for Cancer Clinical Trials (AC3T) A consortium launched under AAI to foster and implement cancer clinical trials led by investigators in Africa, designed to build clinical trial capacity and address the cancer data gap while increasing access to prioritized cancer diagnostics, medicines, and quality treatment.
• Global Innovation Alliance (GIA) An infectious disease program that catalyzes early-stage R&D partnerships with LMIC scientists, builds and promotes clinical trial capabilities in LMICs, elevates scientific expertise, and communicates program outcomes to global audiences.
• GIA Network of Trial Sites (GIANTS) An online platform profiling the infectious disease clinical trial infrastructures, skills, processes, and resources of healthcare and research facilities in LMICs, showcasing institutional capabilities and investigator expertise.
• BVGH Learn A digital learning platform providing on-demand educational content for healthcare and research professionals in LMICs, offering courses on cancer care, clinical trials, and biomedical research that users can access at any time with self-paced lessons, pre/post assessments, instant certificates, and live webinar integration.
• Let's Talk About Cancer A cancer awareness initiative providing educational brochures and patient information booklets targeting specific types of common cancers, with materials available in multiple languages including English, French, Kinyarwanda, Hausa, Igbo, Yoruba, and Pidgin English.
• AC3T Online Platform An interactive web-based platform profiling the cancer clinical trial infrastructures, skills, processes, and resources of healthcare and research facilities in sub-Saharan Africa, featuring interactive maps with filter parameters by country, region, institution type, trial conduct status, and cancer diagnosis/treatment capabilities.

Quantifiable outcome

• 4,000+ cancer patients treated through AAI programs
• +6 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

24 partnerships are on record, tiered core and supporting.

• Takeda Pharmaceutical Co., Ltd.coreStrategic or Co-development PartnerTakeda is a pharmaceutical partner in the African Access Initiative (AAI), contributing to public-private partnerships addressing Africa's cancer crisis. Takeda is one of the founding pharmaceutical partners of AAI alongside Pfizer, joining at the 2017 BIO International Convention launch.
• Johnson & JohnsoncoreStrategic or Co-development PartnerJohnson & Johnson (Janssen Pharmaceutical Companies of Johnson & Johnson) is a pharmaceutical partner in BVGH programs. J&J is involved in the Clinical Trials Community Africa Network (CTCAN) project alongside BVGH, Global Health EDCTP, Science for Africa Foundation, Fondation Mérieux, Medicines Development for Global Health, and nuvoteQ.io.
• Bristol Myers SquibbcoreStrategic or Co-development PartnerBristol Myers Squibb (BMS) is a pharmaceutical partner in the African Access Initiative (AAI), contributing to partnerships addressing Africa's growing cancer burden through drug access and capacity building programs.
• BayercoreStrategic or Co-development PartnerBayer is a pharmaceutical partner in BVGH's African Access Initiative, contributing to cancer care improvement programs in Africa through public-private partnerships.
• AmgencoreStrategic or Co-development PartnerAmgen is a pharmaceutical partner supporting BVGH's African Access Initiative programs addressing cancer care in Africa.
• MEDSERVE / MedServe-LUTH Cancer Centre (MLCC)coreStrategic or Co-development PartnerMEDSERVE is a Nigerian healthcare organization that partners with BVGH on radiotherapy training programs and cancer care improvement in Nigeria. BVGH, NSIA, MedServe, and MLCC launched a first-of-its-kind radiotherapy training program for Nigerian medical physicists, nurses, radiation oncologists, and radiation therapists.
• Nigerian Sovereign Investment Authority (NSIA)coreStrategic or Co-development PartnerNSIA is a financial and strategic partner with BVGH, co-funding and supporting cancer care initiatives in Nigeria. NSIA-LUTH Cancer Centre (NLCC) was established to improve cancer treatment in Nigeria. Dr. Tolulope Adewole of NSIA has publicly credited BVGH for its long-standing support.
• Nigerian Cancer SocietysupportingStrategic or Co-development PartnerNigerian Cancer Society is listed as a select partner of BVGH, collaborating on cancer awareness and advocacy initiatives in Nigeria.
• SIOP Africa (International Society of Pediatric Oncology Africa)coreStrategic or Co-development PartnerBVGH partners with SIOP Africa to deliver pediatric oncology training courses. The AAI & SIOP Africa Advanced Treatment of Pediatric Cancers Part I and Part II trained over 700 healthcare professionals from 73 countries. Also collaborated on ASCO Breast Cancer Management Workshop in Lesotho.
• African Organisation for Research and Training in Cancer (AORTIC)coreStrategic or Co-development PartnerAORTIC is a founding partner of the African Access Initiative (AAI) at the 2017 BIO International Convention launch, contributing oncology research and training expertise to address Africa's cancer crisis.
• Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development PartnerMSK partners with BVGH on oncology training programs, including ICU nursing mentorship for African hospitals (Cameroon) and oncology emergency training. MSK experts deliver lectures and provide virtual mentorship to African healthcare teams.
• University of PennsylvaniacoreStrategic or Co-development PartnerUniversity of Pennsylvania is a key academic partner in BVGH programs, co-mentoring AMPERE fellows, collaborating on radiotherapy research (Prof. Saiful Huq, Prof. Stephen Avery), and contributing faculty to BVGH Learn courses covering data management, statistics, and publication processes.
• American Association of Physicists in Medicine (AAPM)coreStrategic or Co-development PartnerAAPM is a partner in the AMPERE fellowship program alongside BVGH, University of Pennsylvania, and University of Pittsburgh, focused on building the next generation of global medical physics leaders.
• Obafemi Awolowo University, NigeriasupportingStrategic or Co-development PartnerObafemi Awolowo University is a Nigerian academic partner participating in BVGH's clinical trial programs, including the first immunotherapy clinical trial in sub-Saharan Africa targeting colorectal cancer patients.
• Lagos University Teaching Hospital (LUTH), NigeriacoreStrategic or Co-development PartnerLUTH is a core AAI partner hospital in Nigeria. BVGH worked with MedServe and LUTH to develop the MedServe-LUTH Cancer Centre (MLCC) and launch radiotherapy training programs for Nigerian healthcare professionals.
• Global Health EDCTPcoreStrategic or Co-development PartnerGlobal Health EDCTP is a partner in the Clinical Trials Community Africa Network (CTCAN) project with BVGH, contributing to amplifying the capacity of African trial sites and laboratories.
• Science for Africa FoundationcoreStrategic or Co-development PartnerScience for Africa Foundation is a partner in the Clinical Trials Community Africa Network (CTCAN) project with BVGH, supporting site and laboratory network development across Africa.
• Fondation MérieuxsupportingStrategic or Co-development PartnerFondation Mérieux is a partner in the Clinical Trials Community Africa Network (CTCAN) project, contributing to building clinical trial capabilities in Africa alongside BVGH.
• World Intellectual Property Organization (WIPO)coreStrategic or Co-development PartnerWIPO co-led the WIPO Re:Search international public-private consortium with BVGH for 10 years (2012-2022), catalyzing IP-sharing R&D collaborations for neglected tropical diseases, malaria, and tuberculosis. WIPO Re:Search came to a close at end of 2022.
• BeOne MedicinessupportingStrategic or Co-development PartnerBeOne Medicines supplies the drug tislelizumab for the first immunotherapy clinical trial in sub-Saharan Africa, targeting patients with mismatch-repair deficient colorectal cancer in Nigeria.
• ASCP (American Society for Clinical Pathology)supportingStrategic or Co-development PartnerASCP is listed as a select partner of BVGH, supporting pathology and laboratory medicine capacity building programs in Africa.
• Burkitt's Lymphoma Fund for Africa (BLFA)supportingStrategic or Co-development PartnerBLFA collaborated with BVGH and University of Abuja Teaching Hospital on AAI Child Life Practice Training to expand pediatric cancer care in Nigeria.
• American Society of Clinical Oncology (ASCO)coreStrategic or Co-development PartnerASCO provides board-level leadership through Dr. Julie Gralow (CMO and EVP) and collaborates on breast cancer management workshops in Africa. ASCO's Resource Stratified Guideline Advisory Group and Global Curriculum in Medical Oncology are areas of collaboration.
• College of Pathologists of East, Central and Southern Africa (COPESCA)supportingStrategic or Co-development PartnerCOPESCA is listed as a select partner of BVGH, contributing to pathology capacity building across East, Central, and Southern Africa.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Clinton Health Access Initiative (CHAI): CHAI is a global health nonprofit that negotiates market access for medicines and diagnostics in LMICs and runs large multi-country capacity-building programs. Like BVGH, it serves as a public-private convener linking ministries of health, pharma, and global funders, and operates across Africa on cancer, HIV, malaria, and other disease areas.
• PATH: PATH is a global health nonprofit that develops and delivers health solutions, vaccines, diagnostics, and devices in LMICs and runs clinical trial and capacity-building programs across Africa. It shares BVGH's positioning at the intersection of product development, country implementation, and public-private partnership.
• Drugs for Neglected Diseases initiative (DNDi): DNDi is a nonprofit R&D organization that develops new treatments for neglected patients and runs clinical trials in LMICs. It overlaps directly with BVGH's GIA infectious disease work and shares the pharma PPP, African trial-site activation, and capacity-building focus.
• IAVI (International AIDS Vaccine Initiative): IAVI is a nonprofit scientific research organization that accelerates vaccine and antibody R&D for HIV and emerging infectious diseases, with clinical trial activity in Africa and India. It mirrors BVGH's GIA model of pairing LMIC trial-site development with pharma and academic partnerships.
• GHIT Fund (Global Health Innovative Technology Fund): GHIT is a Japanese-led public-private partnership that funds global health R&D by linking Japanese and global pharma with LMIC researchers. Its PPP model, R&D co-development focus, and LMIC trial activity closely mirror BVGH's GIA program.
• AMREF Health Africa: AMREF is an Africa-headquartered nonprofit that delivers community health, training, and clinical services across the continent. It overlaps with BVGH's health-worker training, cancer awareness, and ministry-of-health engagement work, particularly in East Africa.
• Partners in Health: Partners in Health is a global health nonprofit delivering care and training in resource-limited settings, including cancer and infectious disease programs in Africa. It shares BVGH's mission of building durable LMIC clinical capacity alongside government partners.

Broad incumbents

• GAVI, the Vaccine Alliance: GAVI is a much larger global health PPP that funds vaccine access and delivery at scale across LMICs. It shares BVGH's PPP convening model but operates at a fundamentally larger scale and with a more centralized procurement mandate rather than BVGH's niche cancer-and-clinical-trials focus.
• The Global Fund: The Global Fund is a major international financing institution that channels billions into HIV, TB, and malaria programs in LMICs. While not a direct competitor, it defines the broader PPP-driven African health ecosystem in which BVGH operates its AAI and GIA programs.

Others

• AORTIC (African Organisation for Research and Training in Cancer): AORTIC is the pan-African professional society for oncology research and training, and is itself a BVGH partner. It is included as an adjacent ecosystem organization because it defines the same African oncology capacity-building agenda that BVGH's AAI executes.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/bioventures
• Facebookfacebook.com/124039997640383
• LinkedInlinkedin.com/company/bio-ventures-for-global-health
• Instagraminstagram.com/bioventuresforglobalhealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BIO Ventures for Global Health